Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence

Diarrhea Clinical Trial

Official title:

A Multi-center, Randomized, Double-blind, Double-dummy, and Parallel Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Loperamide Hydrochloride/Simethicone Chewable Tablet in the Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02340481
• Other study ID #: CR103534
• Secondary ID: LOPDIR3001
• Status: Completed
• Phase: Phase 3
• First received: January 13, 2015
• Last updated: January 6, 2016
• Start date: July 2005
• Est. completion date: May 2006

Study information

• Verified date: January 2016
• Source: Xian-Janssen Pharmaceutical Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of combined loperamide hydrochloride and simethicone compared to loperamide hydrochloride monotherapy in treating acute diarrhea associated with abdominal discomfort caused by gastrointestinal gas accumulation.

Description:

This is a randomized (the study drug is assigned by chance), double-blind (neither physician nor participant knows the treatment that the participant receives), parallel-group (each group of participants will be treated at the same time), multi-center (when more than one hospital or medical school team work on a medical research study) study. All eligible participants will be randomly assigned to receive either a combination of loperamide hydrochloride and simethicone or loperamide hydrochloride. The study includes Screening Visit (from -24 to 0 hours), Baseline Visit (at 0 hour) and Concluding Visit (within 48 to 96 hours following the start of the trial). The timing of each bowel movement, stool characteristics and the degree and duration of abdominal discomfort caused by gastrointestinal gas accumulation will be recorded for each participant for 48 hours after the first trial drug administration. Participants' safety will be monitored throughout the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 217
• Est. completion date: May 2006
• Est. primary completion date: May 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Participant's symptoms of acute diarrhea must manifest within 48 hours prior to entering the trial

• Participant must have experienced at least three incidences of unformed stool within 24 hours prior to entering the trial (referring to any instances of watery stool or soft stool as determined after placing the stool in a container)

• Participant's most recently produced stool must be unformed stool

• Participant must give a positive answer to the following question: "Have you felt any abdominal discomfort caused by gastrointestinal gas accumulation within the last hour"

• Female participants must take effective contraceptive measures throughout the trial (including oral or injectable contraceptives, contraceptive tools, ligation) or be postmenopausal

Exclusion Criteria:

• Participant hospitalized for treatment of severe acute diarrhea or otherwise requires intravenous fluids or antibiotics on an outpatient basis

• Participant shows an axillary temperature greater than (>) 38.2 degrees Celsius (C) or an oral temperature > 38.6 degrees C

• Participant shows clinical symptoms of bloody or purulent stool or erythrocytes or leukocytes are detected in the participant's stool at > 3 per high power field

• Participant shows a sitting systolic blood pressure less than (<) 90 millimeter of mercury (mmHg) and/ or diastolic blood pressure < 60 mmHg

• Participant is unable to take medication orally or tolerate oral rehydration

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diarrhea
• Flatulence

Intervention

Drug:
• Loperamide hydrochloride + simethicone chewable tablet
Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
• Loperamide hydrochloride
Each capsule contains 2 mg of loperamide hydrochloride
• Loperamide hydrochloride + simethicone chewable placebo tablet
Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
• Loperamide hydrochloride placebo capsule
Placebo matched to loperamide hydrochloride capsule.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Xian-Janssen Pharmaceutical Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to Last Unformed Stool (TTLUS)	The TTLUS is defined as the number of hours from the time the participant first took the trial drug to the last instance of unformed stool, after which the participant only reported formed stool or no stool at all. If no unformed stool was observed at any time during the trial, TTLUS shall be recorded as 0. For participants who withdraw from the trial due to reasons other than complete resolution of the symptoms of diarrhea, TTLUS is defined as the number of hours from the start of the trial to the time of withdrawal.	48 hours	No
Primary	Time to Complete Amelioration of Abdominal Discomfort	The time over which abdominal discomfort caused by gastrointestinal gas accumulation is completely resolved.	48 hours	No
Secondary	Number of Participants With Complete Remission of Diarrhea	Participants who do not produce any unformed stool within 24 hours of producing their last unformed stool shall be regarded as completely resolved of any diarrhea symptoms.	Up to 48 hours	No
Secondary	Number of Unformed Stools	Number of unformed stools produced from first drug administration to the end of treatment.	Up to 48 hours	No
Secondary	Participant's Evaluation of Treatment Efficacy for Diarrhea at the end of Treatment		48 hours	No
Secondary	Number of Participants With Complete Remission of Abdominal Discomfort		Up to 48 hours	No
Secondary	Severity of Abdominal Discomfort	Each participant will evaluate any abdominal bloating and/or abdominal pain and/or any other type of abdominal discomfort caused by gastrointestinal gas accumulation occurring within the last hour on a 5-point scale (0 = none, 1 = mild, 2 = moderate, 3 = relatively severe, 4 = severe).	Up to 48 hours	No
Secondary	Participant's Evaluation of Treatment Efficacy for Abdominal Discomfort		48 hours	No
Secondary	Participant and Investigator's Overall Evaluations of the Treatment		48 hours	No
Secondary	Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)	An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.	Up to 48 hours	Yes